Loading candles…
Laurus Labs Ltd., incorporated in 2005, is a research-focused pharmaceutical and biotechnology company operating in the pharmaceuticals, biotechnology, human and animal health, crop science, and specialty ingredients industries. The company specializes in manufacturing Active Pharmaceutical Ingredients (APIs), including those for anti-retroviral, oncology (with high-potency APIs), cardiovascular, and gastro therapeutics. It also offers integrated Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) services ranging from clinical phase drug development to commercial production. Laurus Labs holds a global leadership position in select APIs and serves as a preferred partner for both innovator and generic pharmaceutical firms. It operates more than 11 manufacturing facilities approved by regulatory agencies such as USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, and TGA. The company employs over 6,500 individuals, including approximately 1,050 scientists.
This page is a live market overview for LAURUS LABS LIMITED (LAURUSLABS) on the NSE. As a listed security, LAURUS LABS LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for LAURUSLABS before placing trades on tick2trade.
As of the latest feed, LAURUSLABS last traded at ₹1,844.3 on NSE, up ₹14.3 (0.78%) from the previous close of ₹1,830. Today's session range is ₹1,833.2 – ₹1,856, against a 52-week band of ₹810.05 – ₹1,856.6. Traded volume today stands at 15.53L shares.
The overview consolidates an interactive price chart with multiple time ranges, a near-the-money option chain snapshot, recent market headlines, upcoming corporate events for LAURUSLABS in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether LAURUSLABS is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for LAURUS LABS LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in LAURUSLABS. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated LAURUSLABS option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 24 Jul 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 30 Apr 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 23 Jan 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 and dividend | 23 Oct 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 25 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 24 Apr 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.